David Lebowitz
Stock Analyst at Citigroup
(1.08)
# 2008
Out of 5,368 analysts
117
Total ratings
47.06%
Success rate
3.12%
Average return
Main Sectors:
| Name | Action | PT | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
BPMC Blueprint Medicines | Upgrades: Neutral | 83 129 | 127.97 | 0.8% | 6 | Jun 4, 2025 | |
EXEL Exelixis | Maintains: Strong Buy | 45 56 | 41.56 | 34.74% | 3 | May 15, 2025 | |
NTLA Intellia Therapeutic... | Maintains: Neutral | 14 10 | 8.31 | 20.34% | 8 | May 9, 2025 | |
CYTK Cytokinetics | Maintains: Buy | 86 80 | 34.38 | 132.69% | 2 | May 7, 2025 | |
PLRX Pliant Therapeutics | Maintains: Neutral | 4 2 | 1.39 | 7.91% | 6 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 45 49 | 39.74 | 23.3% | 4 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 67 64 | 35.58 | 79.88% | 12 | Feb 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Sell | 32 45 | 51.19 | -12.09% | 4 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 97 88 | 67.74 | 29.91% | 5 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Neutral | 38 | 26.13 | 45.43% | 1 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 65 68 | 49.6 | 37.1% | 4 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 70 | 21.24 | 229.57% | 1 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 13 15 | 7.08 | 111.86% | 3 | Sep 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 178 207 | 170.62 | 21.32% | 12 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 39 37 | 21.43 | 72.66% | 9 | May 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 382 | 295.82 | 29.13% | 1 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 103 96 | 56.2 | 70.82% | 3 | Jun 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 18 12 | 1.92 | 525% | 2 | Jul 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 170 164 | 307.82 | -46.72% | 7 | Jul 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 36 39 | 13.45 | 189.96% | 6 | Jun 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 20 21 | 10.24 | 105.08% | 11 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 435 405 | 4.4 | 9104.55% | 1 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 13 14 | 0.62 | 2158.06% | 2 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 324 300 | n/a | n/a | 2 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Underweight | 10 5 | n/a | n/a | 2 | Aug 10, 2021 |